Drug intelligence / Profile preview

simepdekinra

Development stage: Phase 2
Lead developer: DICE Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Simepdekinra is a small molecule drug that acts as an inhibitor of interleukin-17 (IL-17), a pro-inflammatory cytokine involved in the pathogenesis of several autoimmune and inflammatory diseases. It was initially developed by DICE Therapeutics. The drug is currently in Phase 2 clinical trials for the treatment of plaque psoriasis and has also been investigated preclinically for sarcopenia. Its mechanism of action involves inhibiting IL-17 signaling, thereby reducing inflammation associated with conditions like psoriasis[1][2].

Other names: simepdekinra

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on simepdekinra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on simepdekinra.

Explore the full profile